Send to

Choose Destination
Curr Opin Investig Drugs. 2006 Jul;7(7):670-80.

Agomelatine targets a range of major depressive disorder symptoms.

Author information

Department of Molecular Pharmacology and Biological Chemistry, The Feinberg School of Medicine, Center for Drug Discovery and Chemical Biology, Northwestern University, Chicago, IL 60611, USA.


Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center